NCT03278106View on ClinicalTrials.gov

TAS-102 in Treating Advanced Biliary Tract Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

November 30, 2018

Study Completion Date

September 16, 2021

Conditions
CholangiocarcinomaStage III Gallbladder Cancer AJCC v7Stage IIIA Gallbladder Cancer AJCC v7Stage IIIB Gallbladder Cancer AJCC v7Stage IV Gallbladder Cancer AJCC v7Stage IVA Gallbladder Cancer AJCC v7Stage IVB Gallbladder Cancer AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Given PO

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03278106 - TAS-102 in Treating Advanced Biliary Tract Cancers | Biotech Hunter | Biotech Hunter